Given that RELA acted as a tumor suppressor in HCC harboring the TP53R249S mutation, we investigated whether betulinic acid (BetA), a known agonist that promotes RELA activation,[27] exerted antitumor effects in this genetic context. The gene discussed is RELA; the disease is neoplasm.